Clinical Trials
106 trialsA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BioNTech SE
RABBIT
University of Arizona
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
OP-NEU-101
Onchilles Pharma Inc
Agni-01
Obsidian Therapeutics, Inc.
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
PNeoVCA
Mayo Clinic
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Hummingbird Bioscience
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Beijing Tide Pharmaceutical Co., Ltd
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
M.D. Anderson Cancer Center
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Linnaeus Therapeutics, Inc.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Study of GV20-0251 in Participants With Solid Tumor Malignancies
GV20 Therapeutics
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
University of Pittsburgh
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Hadassah Medical Organization
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
MGC018 With or Without MGA012 in Advanced Solid Tumors
MacroGenics
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
START-001
Marengo Therapeutics, Inc.
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
PRESERVE-001
OncoC4, Inc.
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Mural Oncology, Inc
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
ENHANCE
Xynomic Pharmaceuticals, Inc.
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Syndax Pharmaceuticals
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC